CREB-binding protein sequestration by expanded polyglutamine - PubMed

Affiliations

• PMID: 10958659
• DOI: 10.1093/hmg/9.14.2197

CREB-binding protein sequestration by expanded polyglutamine

A McCampbell et al. Hum Mol Genet. 2000.

Abstract

Spinal and bulbar muscular atrophy (SBMA) is one of eight inherited neurodegenerative diseases known to be caused by CAG repeat expansion. The expansion results in an expanded polyglutamine tract, which likely confers a novel, toxic function to the affected protein. Cell culture and transgenic mouse studies have implicated the nucleus as a site for pathogenesis, suggesting that a critical nuclear factor or process is disrupted by the polyglutamine expansion. In this report we present evidence that CREB-binding protein (CBP), a transcriptional co-activator that orchestrates nuclear response to a variety of cell signaling cascades, is incorporated into nuclear inclusions formed by polyglutamine-containing proteins in cultured cells, transgenic mice and tissue from patients with SBMA. We also show CBP incorporation into nuclear inclusions formed in a cell culture model of another polyglutamine disease, spinocerebellar ataxia type 3. We present evidence that soluble levels of CBP are reduced in cells expressing expanded polyglutamine despite increased levels of CBP mRNA. Finally, we demonstrate that over-expression of CBP rescues cells from polyglutamine-mediated toxicity in neuronal cell culture. These data support a CBP-sequestration model of polyglutamine expansion disease.

Similar articles

• [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].

  Sobue G. Sobue G. Rinsho Shinkeigaku. 2000 Dec;40(12):1193-5. Rinsho Shinkeigaku. 2000. PMID: 11464455 Japanese.

• Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.

  Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM. Evers MM, et al. Neurobiol Dis. 2013 Oct;58:49-56. doi: 10.1016/j.nbd.2013.04.019. Epub 2013 May 6. Neurobiol Dis. 2013. PMID: 23659897

• Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.

  Berke SJ, Schmied FA, Brunt ER, Ellerby LM, Paulson HL. Berke SJ, et al. J Neurochem. 2004 May;89(4):908-18. doi: 10.1111/j.1471-4159.2004.02369.x. J Neurochem. 2004. PMID: 15140190

• Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.

  Matos CA, de Macedo-Ribeiro S, Carvalho AL. Matos CA, et al. Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.

• Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.

  Colomer Gould VF. Colomer Gould VF. NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480. NeuroRx. 2005. PMID: 16389311 Free PMC article. Review.

Cited by

• ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3.

  Hernández-Carralero E, Quinet G, Freire R. Hernández-Carralero E, et al. Expert Rev Mol Med. 2024 Sep 25;26:e19. doi: 10.1017/erm.2024.10. Expert Rev Mol Med. 2024. PMID: 39320846 Free PMC article. Review.

• Therapeutic approaches to spinal and bulbar muscular atrophy.

  Ranganathan S, Fischbeck KH. Ranganathan S, et al. Trends Pharmacol Sci. 2010 Nov;31(11):523-7. doi: 10.1016/j.tips.2010.08.005. Epub 2010 Sep 20. Trends Pharmacol Sci. 2010. PMID: 20863580 Free PMC article. Review.

• Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration.

  Katsuno M, Adachi H, Minamiyama M, Waza M, Tokui K, Banno H, Suzuki K, Onoda Y, Tanaka F, Doyu M, Sobue G. Katsuno M, et al. J Neurosci. 2006 Nov 22;26(47):12106-17. doi: 10.1523/JNEUROSCI.3032-06.2006. J Neurosci. 2006. PMID: 17122035 Free PMC article.

• Exclusion of mutations in the PRNP, JPH3, TBP, ATN1, CREBBP, POU3F2 and FTL genes as a cause of disease in Portuguese patients with a Huntington-like phenotype.

  Costa MDC, Teixeira-Castro A, Constante M, Magalhães M, Magalhães P, Cerqueira J, Vale J, Passão V, Barbosa C, Robalo C, Coutinho P, Barros J, Santos MM, Sequeiros J, Maciel P. Costa MDC, et al. J Hum Genet. 2006;51(8):645-651. doi: 10.1007/s10038-006-0001-9. Epub 2006 Jul 21. J Hum Genet. 2006. PMID: 16858508 Free PMC article.

• Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides.

  Vitalis A, Pappu RV. Vitalis A, et al. Biophys Chem. 2011 Nov;159(1):14-23. doi: 10.1016/j.bpc.2011.04.006. Epub 2011 Apr 12. Biophys Chem. 2011. PMID: 21530061 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database